FDA Approves Karyopharm’s Xpovio for Multiple Myeloma

The FDA has granted another approval for Karyopharm’s Xpovio (selinexor), approving the oncology drug for use with two other medications for treating multiple myeloma patients after at least one prior therapy.

The agency’s approval allows the oral drug to be used, in combination with bortezomib and dexamethasone, for treating adult multiple myeloma patients who have been given at least one prior therapy.

Xpovio received FDA approval in June for treating patients with relapsed or refractory diffuse large B-cell lymphoma, and it is currently being reviewed by the European Medicines Agency for patients with heavily pretreated multiple myeloma.